Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Beren Therapeutics

Request full access

Cyclodextrin-based therapeutics for defective cholesterol trafficking conditions

Thousand Oaks, United StatesFounded 2020Biotech & Life Sciences

About Beren Therapeutics

Beren Therapeutics, P.B.C. is a clinical-stage biotechnology company founded in 2020 and co-founded by CEO Jason Camm, who also serves as the Chief Medical Officer of Thiel Capital. Operating as a Public Benefit Corporation, the firm is headquartered in Thousand Oaks, California, with a subsidiary in Japan, Beren Therapeutics K.K., established in 2025. The company focuses on developing and commercializing cyclodextrin-based therapeutics to address a range of intractable diseases characterized by defective cholesterol trafficking.

The core of Beren's technology utilizes the unique ring-shaped structure of cyclodextrins, a type of oligosaccharide, to selectively encapsulate pathogenic compounds. The initial focus is on conditions involving the abnormal accumulation of cholesterol within cells, which is a pathogenic factor in numerous diseases. The company operates in stealth mode alongside its public-facing subsidiary, Mandos LLC, which it uses to advance specific drug programs. In 2021, Beren, through Mandos, acquired the adrabetadex program from Mallinckrodt. This investigational drug recently received Breakthrough Therapy Designation from the U.S. FDA for treating infantile-onset Niemann-Pick disease type C (NPC), a rare genetic disorder.

Beren Therapeutics has secured a total of $130 million in funding across several rounds. Its investors include UTokyo Innovation Platform Company, JIC Venture Growth Investments, Roquette, Alpha Wave Global, and Thiel Capital, among others. The company has established strategic partnerships, including an innovation agreement with Roquette, a global leader in plant-based ingredients and pharmaceutical excipients, to explore the full potential of its cyclodextrin technologies. This collaboration aims to enhance chemistry, manufacturing, and controls (CMC) management and accelerate development. Beren Therapeutics is also actively working to expand its discovery operations into Japan, collaborating with local talent and researchers to grow its pipeline and address unmet medical needs globally.

Source: Dealroom company data

At a glance

Status
Operational
Employees
103
Open positions
None listed
Dealroom signal
84.8/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Drug Development, Cardiology and cardiovascular, Biotech and Pharma
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
DEBTDebt Jun 2026 $165M — Hercules Capital ↗
LATE VCOther financing Jun 2026 $135M $540M Wellington Partners · Eisai · JIC Venture Growth Investments · Founders Fund ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Beren Therapeutics website traffic

Latest recorded traffic for Beren Therapeutics is 5.4K monthly website visits, up 157.1% over the last three months.

Latest monthly visits5.4K 3-month web change+157.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Beren Therapeutics in the Thousand Oaks ecosystem

Live from Dealroom

The Beren Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Roquette

Series B and later6 investors entered at this stage

  • Hercules Capital
  • Wellington Partners
  • Eisai
  • JIC Venture Growth Investments
  • Founders Fund
  • Narya Capital
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States96.9%
🇭🇺 Hungary3.1%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Beren Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Beren Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.